



Alpha-amylase Inhibitory Activity of Sitopaladi Churna: An Ayurvedic Formula

Kolavanahalli Pillegowda Smitha¹, Kuruba Srinivas Kulashekar², Thotlaganahalli Krishnappa Pavithra¹,
Bagepalli Srinivas Ashok Kumar³, Gopi Setty Saran¹

¹ Department of Pharmaceutics, Sri K.V. College of Pharmacy, Chickballapur, Karnataka, India

² Department of Pharmacology, Sri K.V. College of Pharmacy, Chickballapur, Karnataka, India

³ Department of Pharmacognosy, Sri K.V. College of Pharmacy, Chickballapur, Karnataka, India

Received: 07 Jan 2015

Revised: 19 Mar 2015

Accepted: 05 Apr 2015

Abstract

Sitopaladi Churna is an ayurvedic formula, traditionally used as anti-inflammatory, carminative, sedative, expectorant, anti-infective, and various respiratory disorders. The aim of the present study is to screening for alpha amylase (α -amylase) inhibition activity of aqueous extract of Sitopaladi Churna. *In vitro* α -amylase inhibition activity of Sitopaladi Churna was screened by the 3,5-dinitrosalicylic acid method. Sitopaladi Churna showed potent (α -amylase) inhibitory activity with an IC_{50} - 46.38 μ g/ml. Thus, Sitopaladi Churna may consider as a remedy for diabetes and other insulin resistance-related diseases; however, animal and human studies are needed to confirm this activity.

Keywords: Sitopaladi Churna, Ayurvedic Formula, Diabetes, Alpha Amylase, Dinitrosalicylic Acid

Citation: Smitha KP, Kulashekar KS, Pavithra TK, Kumar BSA, Saran GS. Alpha-amylase Inhibitory Activity of Sitopaladi Churna: An Ayurvedic Formula. Trad Integr Med 2016; 1(1): 40-3.

1. INTRODUCTION

Amylase inhibitors are also known as starch blockers because they contain substances that prevent dietary starches from being absorbed by the body. Starches are complex carbohydrates that cannot be absorbed unless they are the first broken down by the digestive enzyme amylase and other secondary enzymes [1].

Salivary and pancreatic amylases catalyze the hydrolysis of glycosidic linkages in starch

and other related polysaccharides, their inhibition have been theorized to have beneficial therapeutic effects by reducing carbohydrate-induced hyperglycemia and hyperinsulinemia [2]. Early studies of commercially available alpha-amylase (α -amylase) inhibitory preparations failed to decrease starch digestion in humans perhaps because of insufficient anti-amylase activity. More recent research utilizing purified amylase inhibitors have demonstrated that these nutrients can rapidly inactivate amylase in human intestinal lumen in a dose-dependent manner and prevent postprandial

Corresponding Author: Bagepalli Srinivas Ashok Kumar
Email: ashok4vani@gmail.com

risers in glucose and insulin [3]. Essentially, it allows the carbohydrates to pass through the system possibly with less caloric intake.

Sitopaladi Churna is an ayurvedic formulation, traditionally used as anti-inflammatory, carminative, sedative, expectorant, anti-infective, and various respiratory disorders. It also increases the appetite, helps digestion, and provides strength to the body. It is recommended for seasonal coughs and colds, as it is a very good expectorant [4]. The present study is to investigate α -amylase inhibitory activity of this ayurvedic formula by *in vitro* method.

2. METHODS

2.1 Preparation of Sitopaladi Churna

Sitopaladi Churna contains vamaslochana (inner white part of *Bombusa arundinacia*), Lavanga Tvak (bark of *Cinnamomum zeylanicum*), Ela (fruit of *Elettaria cardamomum*), Pippali (fruit of *Piper longum*), and Sitophila (Sugar candy). The ingredients were procured from Yucca Enterprises, Mumbai, Maharashtra, India and were made into fine powder, mixed and stored. Sitopaladi Churna was extracted with distilled water by soxhlet apparatus, and extract was dried in vacuum and used for *in vitro* α -amylase inhibitory activity.

2.2 In Vitro α -Amylase Inhibition Assay [3, 5-Dinitrosalicylic Acid (DNSA) Method]

The inhibition assay was performed according to Miller [5] using DNSA method. Varied concentration of dried aqueous extract of Sitopaladi Churna in 500 μ l were added to 500 μ l of 0.02 M sodium phosphate buffer (pH = 6.9 containing 6 mM sodium chloride) containing 0.04 units of α -amylase solution and were incubated at 37° C for 10 minutes, followed by addition of 500 μ l of a 1% of starch solution in 0.02 M sodium phosphate buffer (pH = 6.9). The reaction was stopped with 1.0 ml of DNSA reagent. The test tubes were then incubated in a boiling bath water for 5 minutes and cooled in room temperature. The reaction mixture was then diluted after adding 10 ml of distilled water, and absorbance was measured at 540 nm. The

control samples were also prepared accordingly without any plant extracts and were compared with the test samples containing various concentrations of the plant extracts prepared with different solvents. The results were expressed as % inhibition calculated using the formula:

$$\% \text{ inhibition} = \frac{\text{Ab (control)} - \text{Ab (Test)}}{\text{Ab (control)}} \times 100$$

2.3 Statistical Analysis

IC₅₀ values were calculated by origin Microcol 6.0 software (OriginLab Corporation).

3. RESULTS AND DISCUSSION

The results of α -amylase inhibition activity are shown in figure 1. In the present study, it was observed that all the concentrations (25-1000 μ g) of aqueous extract of Sitopaladi Churna have shown potent α -amylase inhibition activity. The activity reveals concentration dependent nature of Sitopaladi Churna with α -amylase inhibition activity with IC₅₀ value of 46.38 μ g/ml.




Figure 1. Alpha-amylase inhibitory activity of different concentrations of Sitopaladi Churna

Drugs that inhibit carbohydrate hydrolyzing enzymes have been demonstrated to decrease postprandial hyperglycemia and improve impaired glucose metabolism without promoting insulin secretion in non-insulin dependent diabetes mellitus patients. Natural health products of vegetable origin

were clearly indicated as a promising avenue for the prevention of chronic diseases [6].

Postprandial hyperglycemia is one of the risk factors associated with type 2 diabetes mellitus. Digestion of dietary starch α -amylase plays a significant role in elevated blood glucose thus inhibition of amylase enzyme is very useful tool in the management of hyperglycemia [7].

Although the acute effects of α -amylase inhibitors may appear to have therapeutic benefit in patients suffering from diabetes mellitus, obesity, and other insulin resistance-related diseases. Chronic administration in animal models has been shown to induce adverse effects including deleterious histological changes to the pancreas. Because it is unclear if these dietary antinutrients can elicit similar deleterious changes in the pancreatic structure and function of humans [8] the presence of α -amylase inhibitors in human foodstuffs are generally undesirable.

B. arundinacea roots were used in bleeding gums, painful joints, skin eruptions, urinary infections, constipation, leprosy, and fever [9], [10]. *B. arundinacea* has been reported to possess anti-inflammatory, antiulcer [11], antioxidant [12], and antifertility activity [13]. *C. zeylanicum* bark has been traditionally used in uterine

hemorrhage, stomachache, as an antiseptic and an astringent [14]. The scientific studies have confirmed its immunomodulatory activity. It has been also reported to possess remarkable pharmacological effects in the treatment of hyperglycemia [15], [16].

E. cardamomum, fruit is a sweet spice and employed as a medicinal flavoring agent it has been reported to possess antioxidant, anti-inflammatory, appetite stimulant, and carminative [17], [18], [19], [20]. *P. longum* fruit is highly valued in ayurveda for treating several disorders mostly related to indigestion, fever, asthma, and cough [21]. *P. longum* has been reported to possess potent antihyperglycemic and inhibit lipid peroxidation in an alloxan-induced diabetic rats [22]. Thus, Sitopaladi Churna may consider as a remedy for diabetes and other insulin resistance-related diseases; however, animal and human studies are needed to confirm this activity.

6. CONFLICT OF INTERESTS

Authors have no conflict of interests.

7. ACKNOWLEDGMENTS

The authors are thankful to K.V. Naveen Kiran, Chairman of Sri K.V. College of Pharmacy, for providing facilities to carry out this work.

REFERENCES

- [1] Marshall JJ, Lauda CM. Purification and properties of phaseolamin, an inhibitor of alpha-amylase, from the kidney bean, *Phaseolus vulgaris*. *J Biol Chem* 1975; 250(20): 8030-7.
- [2] Puls W, Keup U. Influence of an α -amylase inhibitor (BAY d 7791) on blood glucose, serum insulin and NEFA in starch loading tests in rats, dogs and man. *Diabetologia* 1973; 9(2): 97-101.
- [3] Layer P, Zinsmeister AR, DiMaggio EP. Effects of decreasing intraluminal amylase activity on starch digestion and postprandial gastrointestinal function in humans. *Gastroenterology* 1986; 91(1): 41-8.
- [4] Ramalingayya M, Sastry MV. *Vaidya yoga ratnavali = Formulary of Ayurvedic medicines*. Chennai, India: Indian Medical Practitioners' Co-operative Pharmacy & Stores; 2000. p. 123.
- [5] Miller GL. Use of dinitrosalicylic acid reagent for determination of reducing sugar. *Anal Chem* 1959; 31(3): 426-8.
- [6] Punitha R, Manoharan S. Antihyperglycemic and antilipidperoxidative effects of *Pongamia pinnata* (Linn.) Pierre flowers in alloxan induced diabetic rats. *J Ethnopharmacol* 2006; 105(1-2): 39-46.
- [7] Kwon YI, Vattem DA, Shetty K. Evaluation of clonal herbs of Lamiaceae species for management of diabetes and hypertension. *Asia Pac J Clin Nutr* 2006; 15(1): 107-18.
- [8] Folsch UR, Creutzfeldt W. Adaptation of the pancreas during treatment with enzyme inhibitors in rats and man. *Scand J Gastroenterol Suppl* 1985; 112: 54-63.
- [9] Chopra RN. *Indigenous drugs of India*. 2nd ed. Kolkata, India: U. N. Dhur & Sons Pvt. LTD; 1958. p. 289, 665.
- [10] Khare CP. *Indian medicinal plants: an illustrated dictionary*. New York, NY: Springer Science & Business Media; 2008. p. 90.
- [11] Muniappan M, Sundararaj T. Antiinflammatory and antiulcer activities of *Bambusa arundinacea*. *J Ethnopharmacol* 2003; 88(2-3): 161-7.
- [12] Pérez Trueba LG. Los flavonoides: antioxidantes o prooxidantes. *Rev Cubana Invest Biomed* 2003;

- 22(1): 48-57.
- [13] Vanithakumari G, Manonayagi S, Padma S, Malini T. Antifertility effect of *Bambusa arundinacea* shoot extracts in male rats. *J Ethnopharmacol* 1989; 25(2): 173-80.
- [14] Jayaprakasha GK, Jagan Mohan RL, Sakariah KK. Volatile constituents from *Cinnamomum zeylanicum* fruit stalks and their antioxidant activities. *J Agric Food Chem* 2003; 51(15): 4344-8.
- [15] Kar A, Choudhary BK, Bandyopadhyay NG. Comparative evaluation of hypoglycaemic activity of some Indian medicinal plants in Alloxan diabetic rats. *J Ethnopharmacol* 2003; 84(1): 105-8.
- [16] Verspohl EJ, Bauer K, Neddermann E. Antidiabetic effect of *Cinnamomum cassia* and *Cinnamomum zeylanicum* in vivo and in vitro. *Phytother Res* 2005; 19(3): 203-6.
- [17] Sengupta A, Ghosh S, Bhattacharjee S. Dietary cardamom inhibits the formation of azoxymethane-induced aberrant crypt foci in mice and reduces COX-2 and iNOS expression in the colon. *Asian Pac J Cancer Prev* 2005; 6(2): 118-22.
- [18] Al-Harhi MA. Impact of supplemental feed enzymes, condiments mixture or their combination on broiler performance, nutrients digestibility and plasma constituents. *International Journal of Poultry Science* 2006; 5(8): 764-71.
- [19] Singh G, Kiran S, Marimuthu P, Isidorov V, Vinogorova V. Antioxidant and antimicrobial activities of essential oil and various oleoresins of *Elettaria cardamomum* (seeds and pods). *Journal of the Science of Food and Agriculture* 2008; 88(2): 280-9.
- [20] Verma SK, Jain V, Katewa SS. Blood pressure lowering, fibrinolysis enhancing and antioxidant activities of cardamom (*Elettaria cardamomum*). *Indian J Biochem Biophys* 2009; 46(6): 503-6.
- [21] Dev S. A selection of prime ayurvedic plant drugs: ancient-modern concordance. Delhi, Indian: Anamaya Publishers; 2006.
- [22] Manoharan S, Silvan S, Vasudevan K, Balakrishnan S. Antihyperglycemic and antilipidperoxidative effects of piper longum (Linn.) dried fruits in Alloxan induced diabetic rat. *Journal of Biological Sciences* 2007; 7: 161-8.